Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY – Get Free Report) gapped down prior to trading on Thursday. The stock had previously closed at $17.43, but opened at $16.70. Daiichi Sankyo shares last traded at $17.2450, with a volume of 13,443 shares.
Analysts Set New Price Targets
DSNKY has been the topic of several recent analyst reports. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Zacks Research raised shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Wednesday. Two analysts have rated the stock with a Hold rating. According to MarketBeat, the company has an average rating of “Hold”.
Get Our Latest Report on DSNKY
Daiichi Sankyo Stock Performance
The business’s fifty day moving average is $17.72 and its two-hundred day moving average is $17.50. The company has a quick ratio of 1.96, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $31.46 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 2.05 and a beta of -0.10.
Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.08. Daiichi Sankyo had a return on equity of 16.31% and a net margin of 12.13%. The company had revenue of $3.77 billion for the quarter, compared to analysts’ expectations of $3.58 billion. As a group, research analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 1.05 EPS for the current fiscal year.
About Daiichi Sankyo
Daiichi Sankyo is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions. Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib).
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
